Collegium Pharmaceutical Q3 net income falls 31% to $21.76 million

By Public Technologies
  • Collegium Pharmaceutical’s third-quarter 2026 GAAP net income fell 31% year-over-year to $21.8 million.
  • Quarterly net revenues rose to $216.3 million.
  • JORNAY PM net revenues climbed 24% year-over-year to $51.9 million, while pain portfolio net revenues dropped 18% to $138 million.
  • The $50 million accelerated share repurchase program is expected to settle in the fourth quarter of 2026.
  • Full-year 2026 net revenues guidance was reaffirmed at $825 million to $855 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Collegium Pharmaceutical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611050730PRIMZONEFULLFEED9870726) on November 05, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.